Clinical Trials Logo

Clinical Trial Summary

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05336409
Study type Interventional
Source Century Therapeutics, Inc.
Contact Nikolaus Trede
Phone 888-506-7670
Email ClinicalTeamCNTY@centurytx.com
Status Recruiting
Phase Phase 1
Start date January 24, 2023
Completion date August 2027

See also
  Status Clinical Trial Phase
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Completed NCT04038359 - A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma Phase 2
Completed NCT04136756 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma Phase 1
Active, not recruiting NCT00075478 - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Phase 3
Completed NCT02242045 - Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) Phase 1
Completed NCT01231412 - Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase 3
Active, not recruiting NCT02566304 - Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Recruiting NCT04223765 - Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Phase 1
Active, not recruiting NCT03035331 - Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT05876923 - The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients N/A
Completed NCT00723099 - Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Phase 2
Active, not recruiting NCT03105336 - A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Phase 2
Withdrawn NCT04372641 - Testing the Safety of CB-5339 in Patients With Cancer Phase 1
Completed NCT01882803 - A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma Phase 2
Active, not recruiting NCT04323956 - Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma Phase 1
Active, not recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Recruiting NCT05783596 - Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma Phase 2
Active, not recruiting NCT03749018 - Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Phase 2
Active, not recruiting NCT03884998 - Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma Phase 1
Terminated NCT01944943 - Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia Phase 2